强生皮下注射版Amivantamab获准用于所有先前获批的静脉注射适应症

美股速递
Feb 24

强生公司宣布,其皮下注射(SC)剂型的Amivantamab现已获得授权,可用于所有先前已获批的静脉注射(IV)Amivantamab的适应症。这一授权意味着该药物在更便捷的给药方式下,其应用范围得到了正式扩展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10